CTTQ
Status and phase
Conditions
Treatments
About
TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth daily.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
3)Doppler ultrasound evaluation: Left ventricular ejection fraction(LVEF)≥50% 5.Patients should be voluntary and sign the informed consent before taking part in the study
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Yongmei Yin, Doctor; ZeFei Jiang, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal